Valerion Therapeutics Presents On The Development Of A Humanized Antibody Platform At The International Myotonic Dystrophy Consortium Meeting, Paris, France.

June, 2015

PARIS, FRANCE,  June 2015 – Dustin Armstrong, PhD, Chief Scientific Officer of Valerion Therapeutics along with Ona McConnell, and Eric Wang, PhD, Department of Biology, Massachusetts Institute of Technology, presented on the Development of a humanized antibody platform, VAL-1205 capable of enhanced  delivery of intracellular-targeted therapeutics at The International Myotonic Dystrophy Consortium Meeting on June 11th, 2015 in Paris, France.

Final IDMC Poster